Wambolt & Associates’s Evoke Pharma EVOK Stock Holding History

Wambolt & Associates’s Portfolio EVOK Stock Details EVOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-222	Closed	-$15K	–	239
2022 Q1	$15K	Hold	222	–	–	0.01%	237
2021 Q4	$18K	Hold	222	–	–	0.01%	240
2021 Q3	$39K	Hold	222	–	–	0.02%	239
2021 Q2	$42K	Hold	222	–	–	0.02%	245
2021 Q1	$59K	Hold	222	–	–	0.03%	214
2020 Q4	$83K	Hold	222	–	–	0.05%	204
2020 Q3	$150K	Hold	222	–	–	0.11%	177
2020 Q2	$113K	Hold	222	–	–	0.09%	176
2020 Q1	$37K	Hold	222	–	–	0.04%	158
2019 Q4	$52K	Sell	222 -8	-3%	-$1.37K	0.04%	167
2019 Q3	$29K	Hold	230	–	–	0.02%	157
2019 Q2	$21K	Hold	230	–	–	0.02%	158
2019 Q1	$24K	Hold	230	–	–	0.02%	151
2018 Q4	$82K	Buy	+230	New	+$85.1K	0.09%	143

Other funds holding EVOK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Wambolt & Associates's EVOK Position: Q2 2022 in Review

Wambolt & Associates sold out of Evoke Pharma (EVOK) in Q2 2022, closing a stake of 222 shares — an estimated $15K sold.

Wambolt & Associates first reported a position in EVOK in Q4 2018 and held it in 14 quarters. The position peaked at $150K in Q3 2020. 12 funds tracked by Wall St. Rank hold EVOK as of Q2 2022.

Wambolt & Associates reported no remaining Evoke Pharma position as of Q2 2022 after selling out during the quarter.
Wambolt & Associates sold 222 Evoke Pharma shares in Q2 2022, an estimated $15K.
Wambolt & Associates first reported a position in Evoke Pharma in Q4 2018 and held it in 14 quarters.
Wambolt & Associates's Evoke Pharma position peaked at $150K in Q3 2020.
12 funds tracked by Wall St. Rank held Evoke Pharma as of Q2 2022.

Based on Wambolt & Associates's 13F filing for Q2 2022, filed 1 Aug 2022.